一次情報の記録

重要その他

Kura Oncology reaches FDA alignment on darlifarnib registrational study in HRAS-mutant SGC

Kura Oncology announced FDA alignment on the design of an approximately 40-patient single-arm monotherapy registrational study of darlifarnib in HRAS-mutant salivary gland cancer. The company plans to initiate the study in the first half of 2027, providing a potential path to a second product approval.

主要事実

提出
2026年11月10日 21:05
イベント
その他
方向
中立
アセット
darlifarnib
出典
SEC 8-K
信頼度
出典あり
カレンダー
試験結果発表 · 2027年1月1日

出典の抜粋

EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports THIRD Quarter 2026 Financial Results AND CORPORATE UPDATE – KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% – – KOMZIFTI maintained majority share of new patient starts of the menin inhibitor class in the R/R NPM1-mutated AML market – – Eight abstracts accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations, highlighting expanding development of ziftomenib in AML – – FDA alignment for approximately 40-patient monotherapy registrational study of darlifarnib in HRAS-mutated salivary gland cancer; study initiation targeted for 1H 2027 – – Darlifarnib combination studies in renal

SEC 8-K

Kura Oncology reaches FDA alignment on darlifarnib registrational study in HRAS-mutant SGC | SimianX AI